Announcement Summary

Entity name

MGC PHARMACEUTICALS LTD

Announcement Type

New announcement

Date of this announcement

1/8/2023

The Proposed issue is:

☑ An offer of securities under a securities purchase plan

Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan

ASX +security code	+Security description	Maximum Number of +securities to be issued
New class-code to be confirmed	Attaching options exercisable at \$0.003 expiring 31 July 2026	583,853,943
MXC	ORDINARY FULLY PAID	1,167,707,885

+Record date

31/7/2023

Offer closing date

18/8/2023

+Issue date

24/8/2023

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

MGC PHARMACEUTICALS LTD

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

Registration Number

ACN

116800269

1.3 ASX issuer code

MXC

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

1/8/2023

1.6 The Proposed issue is:

☑ An offer of +securities under a +securities purchase plan

Part 4 - Details of proposed offer under securities purchase plan

Part 4A - Conditions

4A.1a Conditions

Approval/Condition
+Security holder approval

5/9/2023

Date for determination
| Is the date estimated or actual?
| ** Approval received/condition met?

Comments

Shareholder approval is required for the issue of the free-attaching options to SPP participants and a participating Director.



Part 4B - Offer details

Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued

ASX +security code and description

MXC: ORDINARY FULLY PAID

Will the proposed issue of this +security include an offer of attaching +securities? ✓ Yes

Details of +securities proposed to be issued

ASX +security code and description

MXC: ORDINARY FULLY PAID

Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted

1,167,707,885

Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)? ✓ No

Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)? ☑ No

Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)? Yes

Is the minimum acceptance unit based or dollar based? ☑ Dollar based (\$)

Please enter the minimum acceptance value

\$ 1.000

Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)?

Yes

Is the maximum acceptance unit based or dollar based? ☑ Dollar based (\$)

Please enter the maximum acceptance value

\$30,000

Describe all the applicable parcels available for this offer in number of securities or dollar value

\$1,000, \$2,500, \$5,000, \$7,500, \$10,000, \$15,000, \$20,000, \$30,000

Offer price details

Has the offer price been determined? Yes

In what currency will the offer

What is the offer price per

be made?

+security?

AUD - Australian Dollar

AUD 0.00230

Oversubscription & Scale back details

Will a scale back be applied if the offer is over-subscribed? Yes

Describe the scale back arrangements

In the event of a Scale Back the Company intends to prioritise allocations to retail Eligible Shareholders over institutional Eligible Shareholders (as determined by the Company). However, the Company may in its absolute discretion determine to apply the Scale Back to the extent and in the manner it sees fit.

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? ✓ Yes

Attaching +Security

The proposed attaching security can only be of an 'Existing class' (additional +securities in a class that is already quoted or recorded by ASX) New class

Attaching +Security - New class (+securities in a class that is not yet quoted or recorded by ASX)

Details of attaching +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities are non CDIs)

Have you received confirmation from ASX that the terms Will the entity be seeking quotation of the 'new' class of of the proposed +securities are appropriate and equitable under listing rule 6.1? **⊗** No

+securities on ASX? ☑ No

ASX +security code

+Security description

New class-code to be confirmed	

Attaching options exercisable at \$0.003 expiring 31 July 2026

+Security type

Options

Offer ratio (ratio of attaching securities at which the new +securities will be issued)

The quantity of attaching +securities to be issued

For a given quantity of the new +securities issued

1

2

What will be done with fractional entitlements?

Fractions rounded down to the nearest whole number or fractions disregarded

Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted

583,853,943

Offer price details

Has the offer price been determined?

Yes

In what currency will the offer be made?

AUD - Australian Dollar

What is the offer price per +security?

AUD 0.00000

Please confirm whether the offer of the attaching +securities is a separate offer to the offer pursuant to the +security purchase plan

✓ Yes

Please confirm whether the attaching +securities are being offered under a +disclosure document or +PDS

✓ Yes

Oversubscription & Scale back details

Will a scale back be applied if the offer is over-subscribed?

Yes

Describe the scale back arrangements

In the event of a Scale Back the Company intends to prioritise allocations to retail Eligible Shareholders over institutional Eligible Shareholders (as determined by the Company). However, the Company may in its absolute discretion determine to apply the Scale Back to the extent and in the manner it sees fit.

Options details

+Security currency

AUD - Australian Dollar

Exercise priceExpiry dateAUD 0.003031/7/2026

Details of the type of +security that will be issued if the option is exercised

MXC: ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

One Fully Paid Ordinary Share will be issued for every one option exercised.

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

Refer to Announcement dated 1 August 2023.

Part 4C - Timetable

4C.1 Date of announcement of +security purchase plan

1/8/2023

4C.2 +Record date

31/7/2023

4C.3 Date on which offer documents will be made available to investors

3/8/2023

4C.4 Offer open date

4/8/2023

4C.5 Offer closing date

18/8/2023

4C.7 +Issue date and last day for entity to announce results of +security purchase plan offer

24/8/2023

Part 4D - Listing Rule requirements

4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements? Yes

Part 4E - Fees and expenses

4E.1 Will there be a lead manager or broker to the proposed offer?

☑ No

	4E.2 Is the proposed offer to be underwritten? ☑ No
r	4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission? ジ No
4	4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed off
4F	F - Further Information
4	F - Further Information 4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue Production costs, raw material and laboratory costs associated with production of the Company¿s GMP cannabinoid medicines CannEpil and CogniCann, as well as to service existing debt, corporate and audit costs and ongoing workin capital.
4	AF.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue Production costs, raw material and laboratory costs associated with production of the Company¿s GMP cannabinoid medicines CannEpil and CogniCann, as well as to service existing debt, corporate and audit costs and ongoing workin capital. 4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?
4	AF.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue Production costs, raw material and laboratory costs associated with production of the Company¿s GMP cannabinoid medicines CannEpil and CogniCann, as well as to service existing debt, corporate and audit costs and ongoing workin capital. 4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful? No 4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer
4	AF.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue Production costs, raw material and laboratory costs associated with production of the Company¿s GMP cannabinoid medicines CannEpil and CogniCann, as well as to service existing debt, corporate and audit costs and ongoing workir capital. 4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?
4	AF.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue Production costs, raw material and laboratory costs associated with production of the Company¿s GMP cannabinoid medicines CannEpil and CogniCann, as well as to service existing debt, corporate and audit costs and ongoing workin capital. 4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful? No 4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer All holders residing outside of Australia will not be eligible to accept the proposed offer. 4F.3 URL on the entity's website where investors can download information about the proposed offer
4	AF.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue Production costs, raw material and laboratory costs associated with production of the Company¿s GMP cannabinoid medicines CannEpil and CogniCann, as well as to service existing debt, corporate and audit costs and ongoing workin capital. 4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful? No 4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer. All holders residing outside of Australia will not be eligible to accept the proposed offer.
4	AF.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue Production costs, raw material and laboratory costs associated with production of the Company's GMP cannabinoid medicines CannEpil and CogniCann, as well as to service existing debt, corporate and audit costs and ongoing working capital. 4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful? No 4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer. All holders residing outside of Australia will not be eligible to accept the proposed offer. 4F.3 URL on the entity's website where investors can download information about the proposed offer